Mainstream

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Exagen outlines $65M–$70M 2025 revenue target and positive adjusted EBITDA trajectory while advancing biomarker pipeline

Post ContentxgnRead More

You might also be interested in reading Metaplanet turns to Bitcoin leverage for $500M buyback after stock value slips below BTC stash.

July 29, 2025
In Mainstream